Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)
Author:
Affiliation:
1. Kobe City Medical Center General Hospital, Kobe
2. Kanagawa Cancer Center, Yokohama
3. Yujin-Yamazaki Hospital, Hikone
4. Tenri Hospital, Tenri
5. Eli Lilly Japan K.K., Kobe
6. Japan Anti-Tuberculosis Association, Tokyo, Japan
Funder
Eli Lilly and Company
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Link
http://academic.oup.com/jjco/article-pdf/47/4/350/26577101/hyx010.pdf
Reference14 articles.
1. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent;Adjei;Clin Cancer Res,2004
2. Updated clinical information on multitargeted antifolates in lung cancer;Scagliotti;Clin Lung Cancer,2009
3. Consensus statement for the diagnosis and treatment of drug-induced lung injuries;Kubo;Respir Invest,2013
4. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients;Nakagawa;Jpn J Clin Oncol,2008
5. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer;Ohe;Clin Cancer Res,2008
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Case report: Checkpoint inhibitor pneumonitis with positive anti-melanoma differentiation-associated gene 5 antibodies in a patient with lung cancer;Frontiers in Immunology;2024-01-12
2. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021;Therapeutic Advances in Drug Safety;2024-01
3. Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report;Respiratory Medicine and Research;2023-06
4. Anti-Mi-2 antibody-positive lung cancer-associated polymyositis;International Cancer Conference Journal;2023-03-14
5. Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer;Scientific Reports;2023-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3